📄 Read our new white paper: ‘ The Case for Smarter GLP-1 Utilization: Cost, Coverage, and Clinical Outcomes '

Media & press

Latest

Article

Phenomix Sciences Expands Evidence for MyPhenome™ Test Predicting GLP-1 Response and Obesity Risk in Large, Diverse Populations

Menlo Park, Calif.

November 4, 2025

Studies presented at Obesity Week 2025 validate the test’s ability to predict weight-loss response to GLP-1 drugs like semaglutide, including in diverse patient populations and post-bariatric surgery patients.

Read article

No items found.